Serum Institute of India to acquire stake in IntegriMedical
IntegriMedical's N-FIS technology employs a high-velocity jet stream to administer drugs and biologics.
Vaccine manufacturer the Serum Institute of India (SII) has
announced plans to make a strategic investment in IntegriMedical, acquiring a
stake of 20%, to progress the development of needle-free injection system (N-FIS)
technology.
The investment aligns with SII’s strategy to enhance patient
compliance, lower needle-stick injuries and improve the efficacy of liquid
medications.
N-FIS technology employs a mechanically powered
high-velocity jet stream to administer drugs and biologics.
The system is designed to offer a pain-free experience to
patients, particularly those with needle phobia, making the process of
medication administration more pleasant and stress-free.
N-FIS has secured regulatory approvals in India, Europe and
the US. It holds International Organisation for Standardisation 13485
certification and a US patent.
Read more@ https://www.pharmaceutical-technology.com/news/serum-institute-of-india-integrimedical/?cf-view
Comments
Post a Comment